- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$1,010.13 MnMarket Estimate, 2026
$1101.04 MnMarket Forecast, 2034
$2193.89 MnCAGR, 2026–2034
9.0%Executive Summary: North America HIV Diagnostics Market
- Market Scope: Comprehensive North American HIV diagnostics market analysis covering complex testing classifications, diagnostic infrastructure, end-user settings, and regional demand across the U.S. and Canada.
- Market Valuation: Valued at USD 1,010.13 million (2025), estimated at USD 1,101.04 million (2026), and projected to reach USD 2,193.89 million by 2034, registering a robust CAGR of 9.0% (2026–2034).
- Primary Growth Drivers: Significant technological advancements in point-of-care (POC) and rapid diagnostic testing, rising demand for highly accessible and robust screening kits, and the need to overcome laboratory limitations through simplified field-deployable assays.
Key Market Segment Metrics (2026–2034)
| Category | Leading Segment / Benchmark | Fastest-Growing Segment |
|---|---|---|
| By Product | Consumables (Assays, Kits & Reagents) (essential for ongoing high-volume screening operations) | POC Instruments & Rapid Diagnostic Kits (driven by demand for speed and field-accessible testing) |
| By Test Type | Antibody Screening Tests (ELISA/Rapid) (the standard first-line defense for widespread detection) | Viral Load & Early Infant Diagnostics (experiencing high growth for clinical monitoring and early-stage treatment efficacy) |
| By End-User | Diagnostic Laboratories & Hospitals (the primary hubs for high-complexity testing and confirmatory analysis) | Home Care & Specialized Testing Centers (growing due to the shift toward private and at-home diagnostic convenience) |
Major Market Players & Market Structure
Market Structure: A highly diversified landscape comprising multinational diagnostic corporations and innovative health-tech firms, focusing heavily on regulatory-approved, rapid-result assay development. North America remains a global leader, holding over 38% of the global IV diagnostics market share.
Key Companies: Abbott Healthcare, Roche Diagnostics, Siemens Healthcare, Gilead Sciences, ViiV Healthcare, BD Biosciences, bioMérieux, QIAGEN, Sysmex, Beckman Coulter, and others.
North America HIV Diagnostics Market Size
As per the research report, the size of the North America HIV diagnostics market was valued at USD 1,010.13 million in 2025, estimated at USD 1101.04 million in 2026, and is projected to reach USD 2193.89 million by 2034, growing at a CAGR of 9.0% from 2026 to 2034.
The human immunodeficiency virus (HIV) is a kind of retrovirus that causes (AIDS). HIV affects some immune cells, and it weakens the immune system bringing about a loss of capacity to fight against the organisms that cause diseases.
HIV spreads through the exchange of fluids with an infected individual, for example, blood exchange or sharing needles with somebody who is HIV infected. Additionally, HIV can be passed from an infected mother to her child during pregnancy. Some symptoms of HIV disease are weakness, slight fever, swollen glands, cerebral pains, and muscle hurts. The present situation is that various POC/rapid tests are under clinical advancement and examination in the product pipelines of significant market members and are expected to receive regulatory approval in various local segments of the market. This normal increment in the quantity of item offerings to the global market space is required to fuel the development of the HIV diagnostics industry over the forecast period.
Major factors driving the market are the technological advancement of disease diagnostic tests and the foreseen improvement and commercialization of novel, regulatory authorities-approved POC and rapid CD4, p24 antigen, and EID tests; it is expected that all the major regional market segments will witness an expansion in market demand over the forecast period. As a result, there is a need to increase the introduction of easily accessible, efficient, robust diagnostic tests. Because of the financial resource-constrained settings in a massive share of the disease-affected regions, it is not yet feasible to perform the current complex screening, staging, and monitoring tests. This is either because of the absence of adequate testing labs or the absence of prepared clinical technicians capable of performing the tests. These limitations of laboratory-based testing catalyze the improvement of convenient and simple to execute point care and rapid tests.
The North America HIV Diagnostics Market is categorized based on Product, End-User, Type, and geography. The market is divided into Instruments, Consumables (Assays and Kits & Reagents, Other consumables), Software & Services. Based on Type, the market is segmented into HIV-2 & Group O Diagnostic Tests, Antibody Tests, Viral Identification Tests, Viral Load Testing, CD4 Testing, and Early Infant Diagnostics. Further, based on Antibody tests, the market is segmented into (HIV-1 Screening tests- Elisa/EIA, Home Access Dried blood spots. Rapid Tests), (HIV-1 Antibody Confirmatory Tests- Western Blot Test, Line immunoassays (Cnf), Indirect immunofluorescence Assays (IFA), Radio immunoprecipitation Assays (RIPA)). Based on HIV-2 & Group O Diagnostic Tests, the market is further categorized into Blood Antibody Tests, Line Immuno Assay (HIV-2), DBS Tests, and Viral Identification Tests; the market is divided into Qualitative PCR Tests, p24 Antigen tests, and Viral Culture. The North American market is analyzed under various regions, namely the U.S and Canada. The IV Diagnostics Market was dominated by North America, with an overall market share of over 38% globally. North America was followed by Asia Pacific.
KEY MARKET PLAYERS
A few of the notable players operating in the North American HIV diagnostics market include
- Abbott Healthcare
- Alere Inc.
- AbbVie
- Bristol-Myers Squibb
- Gilead Sciences
- Merck & Co. Inc.
- Janssen Therapeutics
- BD Biosciences
- ViiV Healthcare
- Partec
- Sysmex
- Beckman Coulter
- Apogee Flow Systems
- Mylan Inc.
- PointCare Technologies Inc.
- Zyomyx Inc.
- Roche Diagnostics
- Siemens Healthcare
- QIAGEN
- bioMérieux
MARKET SEGMENTATION
This research report on the North American HIV diagnostics market has been segmented & sub-segmented into the following categories
By Product
- Consumables
- Assays
- Kits & Reagents
- Others
- Instruments
- Software
- Services
By Test Type
- Antibody Tests
- HIV Screening Tests
- Elisa
- Rapid Tests
- Home Access Dried Blood Spots
- HIV-1 Antibody Confirmatory Tests
- Western Blot Tests
- Indirect Immunofluorescence Assays (IFA)
- Line Immunoassays
- Radio-Immunoprecipitation Assays
- HIV-2 & Group O Diagnostic Tests
- Blood Antibody Tests
- DBS Tests
- Line ImmunoAssay (HIV-2)
- Viral Identification Tests
- p24 Antigen Test
- Qualitative PCR Tests
- Viral Culture
- CD4 Testing
- Viral load testing
- Early Infant Diagnostics
By End-User
- Diagnostic Laboratories
- Hospitals
- Blood Banks
- Home Care Settings
- Other End-Users
By Country
- The United States
- Canada
- Rest of North America